Common Side Effects of Keytruda and Initial Monitoring
Keytruda (pembrolizumab), an immunotherapy for cancers like melanoma and lung cancer, triggers immune-related adverse events (irAEs) by activating the immune system against tumors, sometimes affecting healthy tissues. Fatigue (up to 50% of patients), rash (30-40%), diarrhea (20-30%), and thyroid issues (10-20%) are most frequent; severe cases include colitis, pneumonitis (lung inflammation, 3-5%), hepatitis, or endocrinopathies.[1][2]
Doctors monitor via regular blood tests, imaging, and symptom checks every 2-3 weeks during infusion cycles. Early detection prevents escalation—patients report symptoms immediately for prompt intervention.
Managing Skin Reactions Like Rash or Itchiness
Topical steroids (e.g., hydrocortisone cream) handle mild rashes; oral prednisone (0.5-1 mg/kg/day) for moderate cases, tapered over weeks. Antihistamines like cetirizine reduce itching. Avoid sun exposure and use moisturizers. In trials, 80% of dermatologic irAEs resolved with these steps.[2][3]
Handling Gastrointestinal Issues Such as Diarrhea or Colitis
Mild diarrhea responds to loperamide (Imodium). Moderate to severe colitis requires oral or IV corticosteroids; infliximab (anti-TNF agent) if no improvement in 48 hours. Hold Keytruda dosing until resolution. Endoscopy confirms diagnosis. Studies show 70-90% recovery with steroids alone.[1][4]
Addressing Endocrine Problems Like Hypothyroidism or Adrenal Insufficiency
Thyroid hormone replacement (levothyroxine) for hypothyroidism; hydrocortisone for adrenal issues. These often persist post-treatment but stabilize with lifelong hormone therapy. Routine TSH testing catches 15-20% of cases early.[2]
Treating Severe Immune Reactions Like Pneumonitis or Hepatitis
High-dose IV steroids (1-2 mg/kg methylprednisolone) are first-line for lung or liver inflammation, confirmed by CT scan or biopsy. Non-responders get infliximab or mycophenolate. Permanently discontinue Keytruda for grade 4 events. FDA data notes pneumonitis mortality under 1% with rapid treatment.[1][3]
When to Hold or Stop Keytruda
Per prescribing info, pause for grade 2 irAEs; resume if grade 0-1 after management. Stop for grade 3-4 recurrence or any grade 3 requiring >10 days steroids. Clinical guidelines prioritize balancing efficacy—Keytruda response rates drop if stopped early, but untreated irAEs risk organ failure.[2][5]
Role of Patient Support and Lifestyle Adjustments
Multidisciplinary teams (oncologist, endocrinologist, dermatologist) coordinate care. Patients hydrate, eat anti-inflammatory diets, and track symptoms via apps. Support groups like Cancer Research UK's forums share experiences. Prophylactic low-dose steroids aren't standard due to efficacy risks.[4]
Differences from Chemotherapy Side Effects Management
Unlike chemo's nausea-focused supportive care (e.g., Zofran), Keytruda demands immunosuppression to counter overactive immunity. Chemo effects are often reversible quickly; irAEs can be chronic.
Sources
[1]: Keytruda Prescribing Information (Merck)
[2]: NCCN Guidelines for Management of Immunotherapy-Related Toxicities
[3]: ASCO Guidelines on Immune-Related Adverse Events
[4]: FDA Keytruda Label Updates
[5]: Memorial Sloan Kettering irAE Management Protocols